Skip to Main Content

Amid growing concern over access to Covid-19 medical products, Moderna (MRNA) has decided not to enforce its patent rights related to its experimental vaccine and will also license its intellectual property to any Covid-19 vaccines to others after the pandemic has ended.

The decision means other companies or governments should not have concerns that the biotech would seek to prevent other Covid-19 vaccines from being developed based on its technology. “We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible,” the company said in a brief statement (here are the patents).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.